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Phenome-wide association studies (PheWAS) have demonstrated utility in validating
genetic associations derived from traditional genetic studies as well as identifying novel
genetic associations. Here we used an electronic health record (EHR)-based PheWAS
to explore pleiotropy of genetic variants in the fat mass and obesity associated gene
(FTO), some of which have been previously associated with obesity and type 2 diabetes
(T2D). We used a population of 10,487 individuals of European ancestry with genome-wide
genotyping from the Electronic Medical Records and Genomics (eMERGE) Network and
another population of 13,711 individuals of European ancestry from the BioVU DNA
biobank at Vanderbilt genotyped using Illumina HumanExome BeadChip. A meta-analysis
of the two study populations replicated the well-described associations between FTO
variants and obesity (odds ratio [OR] = 1.25, 95% Confidence Interval = 1.11–1.24,
p = 2.10 × 10−9) and FTO variants and T2D (OR = 1.14, 95% CI = 1.08–1.21, p = 2.34 ×
10−6). The meta-analysis also demonstrated that FTO variant rs8050136 was significantly
associated with sleep apnea (OR = 1 5.14, 95% CI = 1.07–1.22, p = 3.33 × 10− ); however,
the association was attenuated after adjustment for body mass index (BMI). Novel
phenotype associations with obesity-associated FTO variants included fibrocystic breast
disease (rs9941349, OR = 0.81, 95% CI = 0.74–0.91, p = 5 5.41 × 10− ) and trends toward
associations with non-alcoholic liver disease and gram-positive bacterial infections. FTO
variants not associated with obesity demonstrated other potential disease associations
including non-inflammatory disorders of the cervix and chronic periodontitis. These results
suggest that genetic variants in FTO may have pleiotropic associations, some of which are
not mediated by obesity.
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INTRODUCTION
Pleiotropy, the phenomenon in which a single gene or genetic
variant is associated with multiple phenotypes, is essential to
the functionality of the human genome (Crespi, 2010; Wagner
and Zhang, 2011; Pavlicev and Wagner, 2012). Through com-
paring multiple genome-wide association studies (GWAS) and
candidate gene studies, pleiotropy has been noted in many sin-
gle nucleotide polymorphisms (SNPs) and genes, potentially
providing greater insight into putative biological mechanisms
(Sivakumaran et al., 2011; Stranger et al., 2011; Solovieff et al.,
2013). The increasing prevalence of DNA biobanks linked to rich
phenotype resources and large epidemiological databases have
enabled the development of phenome-wide association study
(PheWAS) method as an additional tool to investigate pleiotropy
(Denny et al., 2010a; Pendergrass et al., 2011). As a complement
to GWAS, PheWAS enables both the validation of genotype-
phenotype associations identified through traditional GWAS and
the generation of new hypotheses, identifying potentially novel
associations as well as putative instances of genetic pleiotropy
(Denny et al., 2011; Pendergrass et al., 2013). A recent applica-
tion of PheWAS to 3144 GWAS-identified variants, replicated 210
known associations and noted 63 new, pleiotropic associations
(Denny et al., 2013).
The Electronic Medical Records and Genomics (eMERGE)
Network was formed in 2007 to use phenotypes derived from
electronic health record (EHR) data to perform GWAS and other
genomic investigations (Kullo et al., 2011; Pathak et al., 2011;
Crosslin et al., 2013; Ding et al., 2013). eMERGE investigators
have also used EHR-based PheWAS methods to evaluate multiple
phenotypes associated with specific genetic variants (Denny et al.,
2010a; Pathak et al., 2012; Hebbring et al., 2013). PheWAS has
been used to enhance our understanding of the genetic determi-
nants of complex traits discovered through GWAS. For example,
a PheWAS of variants associated with longer cardiac conduction
(Ritchie et al., 2013) demonstrated an association with atrial fib-
rillation, and a PheWAS of variants affecting platelet count and
size identified associations with autoimmune diseases (Shameer
et al., 2013).
Variants in the fat mass and obesity associated gene (FTO) have
been studied since 2007, when it was discovered that some were
associated with body mass index (BMI) and obesity (Frayling
et al., 2007). Multiple GWAS have demonstrated further asso-
ciations between variants in FTO and obesity (Jacobsson et al.,
2012). Some of these variants have also been noted to be associ-
ated with both obesity and type 2 diabetes (T2D) (Hertel et al.,
2011; Rees et al., 2011; Li et al., 2012) including SNPs rs9939609
and rs8050136, which are in high linkage disequilibrium (LD)
with each other in people of European ancestry (r2 = 1.00; using
1000 Genomes Pilot 1 reference in the CEU population). The SNP
rs8050136 is located in an intronic region where the transcription
factor cut-like homeobox (CUTL1) protein (Li et al., 2000) is pre-
dicted to bind (Stratigopoulos et al., 2008). This variant has been
associated with T2D and obesity in Han Chinese and European
populations (Hubacek et al., 2008; Liu et al., 2010; Hotta et al.,
2011) but other studies found no association between this variant
and T2D or obesity in the Chinese Han population (Li et al., 2008;
Xi and Mi, 2009). These differences in associations of SNPs with
phenotypes have been further analyzed through fine mapping of
BMI loci (Gong et al., 2013). This study reported that GWAS
studies primarily performed in European populations of numer-
ous loci associated with BMI are not generalizable to other ethnic
groups, for example African Americans. Another study demon-
strated that rs8050136 was associated with increased energy
intake from fat with similar total energy intake (Park et al., 2013).
A more recent study noted that the mechanism of action for com-
mon variants in FTO may be through regulation of IRX3 expres-
sion, which is highly expressed in the brain (Smemo et al., 2014).
There is also evidence of other putative disease associa-
tions with FTO variants that have not achieved genome-wide
significance, such as pancreatic cancer, Alzheimer’s disease, atten-
tion deficit hyperactivity disorder, alcoholism, and osteoarthritis
(Keller et al., 2011; Lurie et al., 2011; Sobczyk-Kopciol et al., 2011;
arcOGEN Consortium et al., 2012; Corella et al., 2012; Reitz et al.,
2012; Velders et al., 2012). These varied disease-SNP associations
suggest that SNPs in FTO may have pleiotropic effects. Utilizing
the population and diagnostic diversity contained within the real-
world clinical environment for variants within FTO, our goal
was to determine whether an EHR-based PheWAS could iden-
tify genetic pleiotropy that might otherwise remain undetected
in traditional cohort study designs. In the present study, we
utilized PheWAS method and data sets from the eMERGE net-
work (McCarty et al., 2011; Gottesman et al., 2013) to evaluate
pleiotropy of variants in FTO.
MATERIALS AND METHODS
PARTICIPATION OF eMERGE SITES
The eMERGE Network data used in this study consists of
seven institutions (Group Health Cooperative and University
of Washington, Marshfield Clinic, Mayo Clinic, Northwestern
University, Mount Sinai, Geisinger Health System, and Vanderbilt
University Medical Center), each with DNA biorepositories
linked to their EHRs. Each site pulled demographic, vital sign,
and billing data from their EHR research data repositories for this
study. All projects were either approved by local IRBs or classified
as IRB exempt as non-human subjects research.
GENOTYPING OF eMERGE SUBJECTS
Variants for eMERGE subjects were selected from extant
genome-wide genotypes with either the Human660W-Quadv1_A
or Illumina OmniExpress chips. The Human660W-Quadv1_A
BeadChip was completed at the Center for Genotyping and
Analysis at the Broad Institute, and the Center for Inherited
Disease Research at Johns Hopkins University. Genotyping
for Illumina OmniExpress BeadChips was performed at the
University of Pittsburgh Genomics and Proteomics Core
Laboratories. These genotyping data comprised 10,487 individ-
uals of European ancestry, as designated in the EHRs.
Quality-control (QC) of the genotype data was performed
using a pipeline developed by the eMERGE Genomics Working
Group (Turner et al., 2011). This process included call rate restric-
tions listed below, identification of sex mismatch and anoma-
lies, checking duplicate and HapMap concordance, as well as
identifying batch effects, sample relatedness, and minor allele
frequency (MAF). Population stratification was evaluated using
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STRUCTURE (Pritchard et al., 2000) and EIGENSTRAT (Price
et al., 2006). Only SNPs with call rates >99% and MAF >0.01
in unrelated samples were included for further study. Relatedness
was determined on the basis of identity by descent (IBD) esti-
mates generated from the genome-wide genotype data in PLINK
(Purcell et al., 2007). All study sites had pairs of individuals with
an IBD estimate greater than 0.25; only one of the individuals in
each related pair was randomly selected and used in the analysis.
Additional genotypes were imputed using IMPUTE2 (Marchini
et al., 2007) and 1000 Genomes Project as the reference (1000
Genomes Project Consortium et al., 2010). We used imputed
SNPs with a minimum info score of 0.7 and called genotypes
based on the maximum posterior probability.
We selected 54 SNPs, of which 51 were imputed in at least
one site, located in FTO that met the QC criteria above and were
previously associated with obesity (Jacobsson et al., 2012). QC
and subsequent association tests were performed using PLINK
(Purcell et al., 2007) and the R statistical package (R Core Team,
2013).
GENOTYPING OF VANDERBILT SUBJECTS USING HumanExome
BeadChips
We selected 13,711 individuals of European ancestry from the
BioVU DNA databank with BMI data who were genotyped
using the Illumina Infinium HumanExome BeadChip, which
includes>240,000 markers, mostly within exonic regions, as well
as SNPs from the GWAS catalog (Welter et al., 2014) including
rs8050136 in FTO. Genotyping was performed at the Vanderbilt
Technologies for Advanced Genomics (VANTAGE) Core, and
genomic data were processed by the Vanderbilt Technologies for
Advanced Genomics Analysis and Research Design (VANGARD)
Core. Clustering was performed using GenomeStudio’s GenTrain
clustering algorithm followed by manual review and reclustering;
genotype calling was performed using GenomeStudio’s GenCall
algorithm. Genotyping quality was evaluated using SNP call rates
and concordance rates withHapMap controls; SNPs with<99.8%
call rate or <98% concordance were excluded. In the first analy-
sis, we focused on rs8050136, which had a call rate of >99.9%.
In the subsequent analyses, we further analyzed eight FTO SNPs
on the Exome chip, which had call rates greater than 99.8% and
MAFs >0.01. Similar to the eMERGE set, for individuals with an
IBD estimate greater than 0.25; only one of the individuals in each
related group was selected randomly and used in our analyses.
PheWAS ANALYSES
We first tested the 54 eMERGE SNPs for association with BMI
using linear regression. We calculated LD with our reference SNP
rs8050136, chosen as the reference because of its GWAS asso-
ciations with BMI and T2D in the literature and since it was
directly genotyped on all of the platforms. To evaluate pheno-
type associations and potential pleiotropy among different FTO
SNPs, we grouped SNPs into three groups for convenience based
on their LD with rs805136: high LD (r2 > 0.80), moderate LD
(0.80 ≥ r2 > 0.60) and low LD (r2 ≤ 0.60) with rs8050136. Our
hypothesis was that SNPs in high LD would show similar patterns
of phenotype associations with rs8050136, and that different
patterns may be observed in SNPs with lower LD.
Analyses for the eMERGE and the BioVU datasets were con-
ducted separately and then meta-analyzed. The eMERGE popu-
lation had 54 SNPs and the BioVU population had nine SNPs
for analysis, which were also present in the eMERGE dataset.
We used logistic regression adjusted for age, sex, eMERGE
site, and the first three principal components as calculated for
each dataset by EIGENSTRAT, using an additive genetic model.
We performed PheWAS using each SNP using methods and
code groupings described previously (Denny et al., 2013) using
the R PheWAS package (Carroll et al., 2014), briefly, calcu-
lating comprehensive associations between SNPs and a total
of 1645 clinical phenotypes derived from the International
Classification of Disease, 9th CM (ICD-9) edition codes from
each site’s EHR. The ICD-9 codes that are associated with
each phenotype can be found at the PheWAS catalog located
online at http://phewas.mc.vanderbilt.edu/. Cases for a given
disease were defined as having at least two relevant ICD-9
codes on different days. The PheWAS method also defines con-
trol groups for each disease, which ensures that related dis-
eases do not serve as controls for the current disease being
analyzed. We performed association testing for all PheWAS
phenotypes occurring in at least 20 individuals (effectively 20
“cases”).
We then compared our results to performing PheWAS for
each FTO SNP adjusting for BMI. The BMI, obtained from each
site’s EHR, was estimated using the average BMI from individu-
als within our dataset. To minimize erroneous data, we only used
BMI measurements between 15 and 70, a range that we have used
in prior studies and has good precision (Denny et al., 2010b).
Plotting was performed in R using the PheWAS and ggplot2
packages.
Meta-analysis was performed using the inverse-variance
method (Hunter et al., 1982) for the nine shared SNPs. There were
1010 phenotypes that were in common across both datasets and
met our minimum case criteria of at least 20 cases. This yields a
Bonferroni corrected p-value of 4.95 × 10−5, (p = 0.05/1010 =
4.95 × 10−5), for a single SNP. We chose a single SNP, phenome-
wide correction threshold since most of the SNPs in this analysis
were in high LD with each other and thus do not represent truly
independent tests. A false discovery rate (FDR) of q = 0.05, cal-
culated with the Benjamin and Hochberg method using the R
p.adjust method, yields a p-value of 2.48 × 10−4 (Benjamini and
Hochberg, 1995). For our latter analyses, we considered a total of
54 SNPs. Since many phenotypes are correlated with each other
andmany of the SNPs are in LD, we also used simpleM (Gao et al.,
2010) to estimate the number of unique tests performed, lead-
ing to an adjustment of p = 2.36 × 10−6. All analyses assumed a
two-tailed distribution.
RESULTS
OVERVIEW
A total of 24,198 individuals were used in our analyses (Table 1).
Both the eMERGE and BioVU datasets were similar in median
age, sex, and BMI. Our analysis of the association of the FTO SNPs
with BMI (Table 2) showed that most SNPs in high linkage dis-
equilibrium with rs8050136 (r2 > 0.80) have highly significant
p-values (< 3 × 10−9) and betas for BMI (Table 2). SNPs with
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Table 1 | Characteristics of the study sets.
eMERGE
n = 10,487
BioVU
n = 13,711
Combined
n = 24,198
Genotyping Platform Illumina Human660W-Quadv1_A Illumina HumanExome
Number of SNPs 54 9 9
Total number of
phenotypes
1094 1254 1010
Median age (IQR) 58 (48–68) 60 (47–72) 59 (48–70)
Female (%) 52.24 54.31 53.35
BMI (average ± SD) 30.86 ± 7.48 28.43 ± 6.44 29.54 ± 7.04
Most frequent diagnoses Hypertension (66%)
Hyperlipidemia (61%)
Pain in limb (47%)
Malaise and fatigue (39%)
Abdominal/pelvic symptoms
(36%)
Hypertension (63%)
Malaise and fatigue
(51%)
Eye infection, viral (50%)
Hyperlipidemia (40%)
Pain in limb (39%)
Hypertension (64%)
Hyperlipidemia (49%)
Malaise and fatigue
(46%)
Pain in limb (43%)
GERD (34%)
This table shows the main characteristics of the study populations of European ancestry, including age, sex, BMI and the five most significant PheWAS phenotypes
observed in the datasets. The sample size included 10,487 from the eMERGE population and 13,711 from the BioVU population for a total of 24,198 people. For a
given phenotype, in the combined dataset our maximum number of cases was 14,592 in hypertension and the minimum number of cases was 44.
lower correlations with rs8050136 have highly variable associa-
tions with BMI.
PheWAS OF FTO rs8050136 UNADJUSTED FOR BMI
In the BioVU population, we observed that obesity (OR = 1.22,
p = 1.4 × 10−6, 95% CI = 1.13–1.33) was significantly associ-
ated with rs8050136. Three obesity-related diseases also trended
toward significance; T2D (OR = 1.14, p = 5.3 × 10−5, 95%CI =
1.07–1.21), obstructive sleep apnea (OSA; OR = 1.15, p = 4.6 ×
10−3, 95% CI = 1.04–1.26) and chronic non-alcoholic liver dis-
ease (NAFLD; OR = 1.20, p = 6.06 × 10−3, 95% CI = 1.05–
1.38) (Supplementary Table 1). We observed similar odds ratios
for obesity and T2D in eMERGE (obesity: OR = 1.37, p =
1.88 × 10−4, 95% CI = 1.16–1.61; T2D: OR = 1.16, p = 0.014,
95%CI = 1.03–1.32). eMERGE results also demonstrated similar
trends toward significant associations with OSA (OR = 1.14, p =
2.4 × 10−3, 95%CI = 1.05–1.24) (Supplementary Table 1). After
meta-analysis, obesity (OR = 1.25, p = 2.1 × 10−9, 95% CI =
1.16–1.35), morbid obesity (OR = 1.34, p = 1.07 × 10−7, 95%
CI = 1.20–1.48), and two obesity-related diseases, T2D (OR =
1.14, p = 2.3 × 10−6, 95% CI = 1.08–1.21) and OSA (OR =
1.15, p = 3.3 × 10−5, 95%CI = 1.07–1.22), were associated with
rs8050136 (Table 3). Additionally, the associations with NAFLD
and fibrocystic breast disease were also q < 0.05.
PheWAS OF FTO rs8050136 ADJUSTED FOR BMI
After adjusting for average BMI, some of the associations were
greatly attenuated, while others remained relatively unchanged
(Table 3, Figure 1). The associations with obesity and OSA
were largely attenuated by adjustment for BMI (obesity:
OR = 1.11, p = 0.017, 95% CI = 1.02–1.22; morbid obesity:
OR = 1.17, p = 0.016, 95% CI = 1.03–1.33; OSA: OR = 1.07,
p = 0.040, 95% CI = 1.00–1.15). Chronic non-alcoholic liver
disease demonstrated a possible association with rs8050136,
which was only slightly attenuated between unadjusted and
BMI-adjusted analyses (OR: 1.23 vs. 1.19; p: 2.2 × 10−4 vs. 1.9 ×
10−3, 95% CI = 1.10–1.37 vs. 1.07–1.33). Additional phenotypes
trended toward association with rs8050136, including fibrocys-
tic breast disease (OR = 0.84, p = 4.8 × 10−4, 95% CI = 0.75–
0.92), staphylococcal infections (OR = 1.16, p = 5.8 × 10−3,
95% CI = 1.04–1.29), streptococcal infections (OR = 1.21,p =
6.6 × 10−3, 95% CI = 1.05–1.39), osteomyelitis (OR = 1.21,
p = 0.011, 95%CI = 1.04–1.41), and joint effusions (OR = 1.22,
p = 6.9 × 10−3, 95% CI = 1.06–1.41). These were not notably
changed by BMI adjustment. Due to the number of gram-
positive bacterial infections, we tested post hoc for the association
between the SNP and a composite phenotype of all gram-positive
infections, which were defined as staphylococcal infections, strep-
tococcal infections, pneumococcal pneumonia, and gram positive
septicemia. When combining all gram-positive phenotypes, the
result was similar to the individual phenotypes (n = 1095, OR =
1.15 95% confidence interval [95% CI] = 1.06–1.26).
PheWAS OF OTHER FTO SNPs ASSOCIATED WITH OBESITY
The results of SNPs in high LD with rs8050136 (r2 > 0.8) showed
a similar pattern of phenotypes to rs8050136 (Figures 2A,B).
Rs9941349, which is in LD with rs8050136 (r2 = 0.92) trended
toward association with cystic mastopathy prior to BMI adjust-
ment (p = 5.4 × 10−5, OR = 0.81, 95% CI = 0.73–0.90). SNPs
with moderate to low correlation with rs8050136 had much
different patterns of associations. Some of these SNPs demon-
strated associations with obesity (e.g., rs9939609, rs9941349),
and some did not (e.g., rs6499640, rs7199182; see Table 2).
Of these SNPs, we only had eMERGE and BioVU data for
rs6499640 (Figure 3A). All other SNPs were only available in
the eMERGE data. “Non-inflammatory disorders of the cervix”
was associated with some FTO SNPs (rs16952520: n = 21, p =
1.92 × 10−6, OR = 6.76, 95% CI = 3.08–14.84), and was unaf-
fected by adjustment for BMI (OR = 6.66, 95% CI = 3.03–
14.64, p = 2.36 × 10−6) (Figure 3B, MAF = 0.087). One less
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Table 2 | Association between FTO variants and average BMI.
SNP Minor allele Major allele MAF Beta (95%CI) p† r2
rs8050136 A C 0.41 0.535 (0.363, 0.707) 1.28E-09 1.00
rs9935401 A G 0.41 0.535 (0.363, 0.707) 1.26E-09 1.00
rs11075990 G A 0.42 0.534 (0.362, 0.706) 1.29E-09 1.00
rs9923233 C G 0.42 0.534 (0.362, 0.706) 1.29E-09 1.00
rs9926289 A G 0.42 0.534 (0.362, 0.706) 1.29E-09 1.00
rs9936385 C T 0.42 0.534 (0.362, 0.706) 1.29E-09 1.00
rs9939609 A T 0.42 0.534 (0.362, 0.706) 1.29E-09 1.00
rs8043757 T A 0.41 0.539 (0.367, 0.711) 9.71E-10 1.00
rs7185735 G A 0.42 0.536 (0.364, 0.708) 1.17E-09 1.00
rs17817449 G T 0.40 0.548 (0.376, 0.720) 5.07E-10 1.00
rs7193144 C T 0.41 0.529 (0.357, 0.701) 1.96E-09 1.00
rs3751812 T G 0.34 0.572 (0.400, 0.744) 9.34E-11 0.99
rs55872725 T C 0.35 0.561 (0.389, 0.733) 1.67E-10 0.94
rs1558902 A T 0.35 0.560 (0.388, 0.732) 1.84E-10 0.94
rs62048402 A G 0.35 0.560 (0.388, 0.732) 1.84E-10 0.94
rs11642015 T C 0.35 0.561 (0.389, 0.733) 1.70E-10 0.94
rs1421085 C T 0.35 0.561 (0.389, 0.733) 1.70E-10 0.94
rs9941349 T C 0.37 0.564 (0.392, 0.736) 1.42E-10 0.92
rs9931494 G C 0.37 0.561 (0.389, 0.733) 1.72E-10 0.92
rs12149832 A G 0.35 0.560 (0.388, 0.732) 1.71E-10 0.90
rs1121980 A G 0.44 0.522 (0.351, 0.693) 2.40E-09 0.88
rs9939973 A G 0.43 0.528 (0.357, 0.699) 1.48E-09 0.88
rs9940646 G C 0.43 0.528 (0.357, 0.699) 1.48E-09 0.88
rs9940128 A G 0.43 0.527 (0.356, 0.698) 1.61E-09 0.88
rs9937053 A G 0.43 0.530 (0.359, 0.701) 1.35E-09 0.88
rs9930333 G T 0.44 0.534 (0.363, 0.705) 9.67E-10 0.88
rs9932754 C T 0.39 0.544 (0.373, 0.715) 4.63E-10 0.85
rs9930506 G A 0.39 0.544 (0.373, 0.715) 4.63E-10 0.85
rs9922619 T G 0.39 0.553 (0.382, 0.724) 2.37E-10 0.85
rs8057044 G A 0.47 0.530 (0.359, 0.701) 1.25E-09 0.72
rs17817288 G A 0.48 0.528 (0.357, 0.699) 1.19E-09 0.68
rs9922047 C G 0.44 0.502 (0.331, 0.673) 7.21E-09 0.64
rs1861866 C T 0.44 0.498 (0.327, 0.669) 9.63E-09 0.64
rs8055197 G A 0.44 0.498 (0.327, 0.669) 9.63E-09 0.64
rs10852521 T C 0.44 0.497 (0.326, 0.668) 1.02E-08 0.64
rs8047395 G A 0.43 0.496 (0.325, 0.667) 1.10E-08 0.64
rs8044769 T C 0.42 0.504 (0.333, 0.675) 6.64E-09 0.62
rs3751813 G T 0.45 0.419 (0.247, 0.591) 2.06E-06 0.57
rs4783819 G C 0.33 0.414 (0.236, 0.592) 5.43E-06 0.41
rs1477196 A G 0.32 0.410 (0.232, 0.588) 6.74E-06 0.40
rs7190492 A G 0.33 0.426 (0.248, 0.604) 2.83E-06 0.40
rs7186521 G A 0.45 0.251 (0.080, 0.422) 3.79E-03 0.09
rs1861869 G C 0.47 0.274 (0.103, 0.445) 1.62E-03 0.08
rs1861868 T C 0.44 0.256 (0.087, 0.425) 3.04E-03 0.08
rs6499640 G A 0.39 0.264 (0.090, 0.438) 3.15E-03 0.06
rs11075986 G C 0.12 0.065 (− 0.251, 0.381) 0.69 0.06
rs16945088 G A 0.12 0.001 (− 0.317, 0.319) 0.99 0.06
rs8063946 T C 0.12 0.101 (− 0.260, 0.462) 0.58 0.04
rs1075440 G A 0.28 0.173 (− 0.011, 0.357) 0.06 0.04
rs16952520 G A 0.09 0.205 (− 0.238, 0.648) 0.36 0.03
rs12447107 C G 0.08 0.246 (− 0.379, 0.871) 0.44 0.01
rs7204609 C T 0.10 0.469 (− 0.111, 1.049) 0.11 0.01
rs7199182 G A 0.06 2.346 (0.472, 4.220) 0.01 0.00
rs1108102 A T 0.03 1.045 (− 1.732, 3.822) 0.46 0.00
Analysis used an additive genetic model and linear regression adjusted for age, sex, and first three principal components using the imputed eMERGE samples. The
SNPs below are sorted by p-value. The beta represents the kg/m2 increase in BMI per minor allele. Linkage disequilibrium (r2) was calculated between rs8050136
(bolded) and other FTO SNPs using the eMERGE imputed set. The Bonferroni correction alpha = 0.05 for 54 SNPs is 9.26 × 10−3.
†Values are not corrected for multiple testing.
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Table 3 | Meta-analysis PheWAS results for rs8050136 with and without adjustment for average BMI.
Phenotype Cases Not adjusted for BMI Adjusted for BMI
p† OR (95% CI) p† OR (95% CI)
Overweight 3943 1.38 × 10−8 1.17 (1.11–1.24) 0.185 1.05 (0.98–1.12)
Obesity 1662 2.10 × 10−9 1.25 (1.16–1.35) 0.017 1.11 (1.02–1.22)
Morbid obesity 756 1.07 × 10−7 1.34 (1.20–1.48) 0.016 1.17 (1.03–1.33)
Type 2 diabetes 3936 2.34 × 10−6 1.14 (1.08–1.21) 4.56 × 10−4 1.09 (1.03–1.15)
Sleep apnea 2335 3.33 × 10−5 1.14 (1.07–1.22) 0.040 1.07 (1.00–1.15)
Cystic mastopathy 967 2.00 × 10−4 0.82 (0.74–0.91) 4.75 × 10−4 0.84 (0.75–0.92)
Chronic Nonalcoholic Liver disease 684 2.22 × 10−4 1.23 (1.10–1.37) 1.86 × 10−3 1.19 (1.07–1.33)
Chronic Ulcer of Leg or Foot 768 8.31 × 10−4 1.19 (1.08–1.32) 2.55 × 10−3 1.17 (1.06–1.30)
Acute Renal Failure 2047 1.12 × 10−3 1.12 (1.05–1.20) 3.74 × 10−3 1.11 (1.03–1.19)
Staphylococcus infections 723 2.44 × 10−3 1.18 (1.06–1.31) 5.76 × 10−3 1.16 (1.04–1.29)
Superficial cellulitis and abscess 2861 5.65 × 10−3 1.09 (1.02–1.15) 0.039 1.06 (1.00–1.13)
Streptococcus infection 428 4.26 × 10−3 1.21 (1.05–1.39) 6.56 × 10−3 1.21 (1.05–1.39)
Osteomyelitis 352 6.15 × 10−3 1.23 (1.06–1.43) 0.011 1.21 (1.04–1.41)
All gram positive infections 1095 6.21 × 10−4 1.16 (1.07–1.27) 1.3 × 10−3 1.15 (1.06–1.26)
Joint effusions 387 2.35 × 10−3 1.25 (1.08–1.44) 6.90 × 10−3 1.22 (1.06–1.41)
This table includes all phenotypes with p-value less than 1.00 × 10−4 prior to BMI adjustment. The Bonferroni alpha = 0.05 equates to a p-value of 4.95 × 10−5, and
an FDR of q = 0.05 gives a p-value of 2.48 × 10−4. OR, Odds ratio; CI, confidence interval. The ICD-9 codes that are associated with each phenotype can be found
at the PheWAS catalog located online at http:// phewas.mc.vanderbilt.edu/ .
†Values are not corrected for multiple testing.
common genetic variant rs7199182 (Figure 3C, MAF = 0.064)
was associated with chronic periodontitis (202 cases,OR = 14.58,
95% CI = 3.97–53.57, p = 5.40 × 10−5), and was not changed
with adjustment for BMI with the signal being slightly stronger
(OR = 14.66, 95% CI = 3.99–53.84, p = 5.20 × 10−5). Neither
rs16952520 nor rs7199182 were associated with obesity or T2D.
Detailed results for selected SNPs are shown in Supplementary
Tables 3, 4.
DISCUSSION
We studied the pleiotropic patterns for FTO variants with and
without adjustment for BMI using phenome-wide associations
in two large EHR cohorts. Consistent with other studies, we
identified statistically significant associations with obesity, mor-
bid obesity, and T2D among SNPs known to be associated with
BMI; these associations were attenuated by adjustment for BMI.
We also identified an association with OSA and trends toward
association with NAFLD, fibrocystic breast disease, and infec-
tions, primarily gram-positive, with obesity-related SNPs. Some
of these potential associations seem independent of BMI adjust-
ment. Fibrocystic breast changes are a common benign breast
disease and traditionally not thought related to obesity, includ-
ing several epidemiological studies (Friedenreich et al., 2000; Baer
et al., 2005; Li et al., 2005). Gram-positive infections could be
explained in part by higher incidence of T2D in genetic vari-
ants of FTO. By analyzing other SNPs not significantly associated
with BMI in our analysis, we also identified a few other potential
associations with less common traits not associated with obesity
(periodontitis, non-inflammatory diseases of the cervix); nei-
ther of these SNPs is in high LD with obesity-related SNPs. The
most common ICD-9 code for “non-inflammatory disorders of
the cervix” is cervical stenosis or stricture not related to con-
genital abnormalities or labor, which can result from surgical
procedures, radiation, trauma, repeated vaginal infections, or
menopause-related atrophy. These results, along with the recent
association of FTO variants with IRX3 regulation (Smemo et al.,
2014), suggest a broader role for FTO beyond that of regulating
fat mass.
The question of whether the association of FTO variants and
T2D is influenced by obesity or both obesity and FTO has been
studied previously. A UK study of 9103 individuals demonstrated
the loss of association after adjustment for BMI, as the T2D-
FTO association prior to adjustment for BMI showed an OR =
1.15, p = 9 × 10−6 and after adjustment showed an OR = 1.03,
p = 0.44 (Frayling et al., 2007). However, other studies suggest
that T2D’s association with FTO remains after adjustment for
BMI (Hertel et al., 2011; Li et al., 2012). Li et al. studied 96,551
East and South Asians and demonstrated an association with
T2D (OR = 1.15, p = 5.5 × 10−8) that was only partially atten-
uated after adjustment for BMI (OR = 1.10, p = 6.6 × 10−5)
(Li et al., 2012). Similarly, Hertel et al. observed a significant
T2D-FTO association even after adjustment for BMI in 41,504
Scandinavians, with the OR prior to adjustment of 1.13, p =
4.5 × 10−8 and after adjustment, OR = 1.09, p = 1.2 × 10−4
(Hertel et al., 2011). Finally a meta-analysis of 24,198 individ-
uals demonstrated FTO rs9939609 (in high LD with rs8050136
with r2 > 0.8) was highly significantly associated with T2D before
and after adjustment for BMI (before adjustment OR = 1.14,
95% CI = 1.12–1.16, p = 1.00 × 10−41; after adjustment OR =
1.07, 95% CI = 1.05–1.09, p = 6.42 × 10−41) (Xi et al., 2014).
However, among individuals of European ancestry, the associa-
tion was markedly attenuated after adjustment for BMI (before
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adjustment OR = 1.14, 95% CI = 1.11–1.16, p = 1.36 × 10−36;
after adjustment OR = 1.06, 95% CI = 1.04–1.09, p = 3.51 ×
10−8). In our study, the association between FTO and T2D did
not decrease after adjustment for BMI as markedly as phenotypes
such as obesity or sleep apnea. The effect sizes of these associa-
tions with T2D in our study closely parallels these larger studies
(before BMI adjustment: OR = 1.14, 95% CI = 1.08–1.21, p =
2.11 × 10−6; after adjustment: OR = 1.09, 95% CI = 1.03–1.15,
p = 2.62 × 10−3). Although these results show an association
of FTO with T2D, a mediation analysis first demonstrating the
associations of FTO SNPs with BMI and pre-diagnostic BMI
with T2D, and subsequently modeling both FTO SNPs and pre-
diagnostic BMI on T2D would help determine the direct and
indirect effects of FTO on T2D.
FIGURE 1 | Continued
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FIGURE 1 | PheWAS plots for FTO rs8050136 with and without BMI
adjustment. The pink horizontal line represents p = 4.95 × 10−5, which is the
Bonferroni correction, and the blue horizontal line represents an FDR q = 0.05
(p = 2.48 × 10−4). (A)without BMI adjustment, (B)with BMI adjustment, and
(C) most significant phenotypic associations before and after BMI adjustment
(BMI-unadjusted values are shown as triangles and average BMI values are
shown as dots) plotted on the same axis. The colors of points indicate the
membership according to the phenotype classes identified on the X axis.
Many of our findings, while having strong signals, were not
significant after Bonferroni correction. The significant associa-
tions using Bonferroni correction included obesity, T2D, and
OSA prior to BMI adjustment. After adjustment for average BMI,
no associations retained statistical significance, but multiple phe-
notypes approached significance including T2D, NAFLD, and the
protective effect on fibrocystic breast disease.
There is still much debate and uncertainty about both phe-
notypic association and protein functionality of FTO. Human
FTO protein expression studies fail to replicate FTO’s associ-
ation with obesity observed in mouse models (Klöting et al.,
2008; Wåhlén et al., 2008; Grunnet et al., 2009). Recent studies
have shown that the SNPs in FTO that are associated with obe-
sity regulate IRX3 expression, which is highly expressed in the
brain (Smemo et al., 2014). Studies have described the associ-
ation between FTO and obesity, while the association between
T2D and FTO is debated (Hubacek et al., 2008; Li et al., 2008;
Xi and Mi, 2009; Liu et al., 2010; Hotta et al., 2011). More stud-
ies with larger populations are required to assess the validity of
many of these associations. The results of these associations show
the power of the PheWAS method to efficiently detect known and
novel pleiotropic associations of genetic variants.
BMI is an inexact surrogate for adiposity. Indeed, individu-
als with a high BMI do not necessarily have a high body fat
percentage, thus BMI may not be the optimal definition of the
phenotype (Müller et al., 2010). However, BMI has been shown
to be as good a surrogate for obesity and diabetes as other central
obesity indicators in multiple studies andmeta-analyses (Vazquez
et al., 2007; Nyamdorj et al., 2008, 2009).
Prior studies have suggested several other phenotypes that
may be associated with FTO variants, including pancreatic can-
cer, Alzheimer’s disease, attention deficit hyperactivity disorder,
and alcoholism (Keller et al., 2011; Lurie et al., 2011; Sobczyk-
Kopciol et al., 2011; arcOGEN Consortium et al., 2012; Corella
et al., 2012; Reitz et al., 2012; Velders et al., 2012). We did not
find evidence for these associations in our data set (p > 0.05)
(Table 4), but in these cases we may be underpowered to find an
association, with case sizes of 76 (attention deficit hyperactivity
disorder), 183 (pancreatic cancer), 192 (Alzheimer’s disease), and
267 (alcoholism) in our population. A trend toward association
between FTO rs8044769 and osteoarthritis was observed in a pre-
vious GWAS study (rs8044769, r2 = 0.647 with rs8050136, p =
4 × 10−6) (arcOGEN Consortium et al., 2012). Our observation
of a trend toward associations with joint effusions, which may be
caused by osteoarthritis, lends some support to this inflammatory
association.
Further analysis of multiple SNPs associated with obesity in
FTO yielded some interesting results. First, the SNPs that are
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FIGURE 2 | PheWAS plots for other obesity associated SNPs in high LD
with rs8050136. These plots show unadjusted values and the average BMI
adjusted values on the same axis. These SNPs are associated with BMI and
have different correlations with rs8050136. These SNPs are present in both
datasets and are presented as meta-analyses below. The pink horizontal line
represents p = 4.95 × 10−5, which is the Bonferroni correction, and the blue
horizontal line represents an FDR q = 0.05 (p = 2.48 × 10−4). (A) rs9939609
is reported widely in the literature and has a nearly identical pattern of
associations to rs8050136 (r2 = 0.96). (B) rs9941349 also has a similar
pattern to rs8050136 but cystic mastopathy is marginally more associated
(p = 5.41 × 10−5, OR = 0.81 before BMI adjustment) than in rs8050136
(r2 = 0.88).
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FIGURE 3 | Continued
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FIGURE 3 | PheWAS plots for other obesity associated SNPs in low LD
with rs8050136. These plots show values without adjustment for BMI
(shown as triangles) and with adjustment for average BMI (shown as dots)
plotted on the same axis. (A) rs6499640 is in both datasets with a lower LD
with rs8050136 (r2 = 0.06) and has a different phenotype pattern than
rs8050136 (B) rs16952520 is only present in the eMERGE population and has
low LD with rs8050136 (r2 = 0.03) and while not strongly associated with
obesity or diabetes does show significant association with non-inflammatory
disorders of the cervix (OR = 6.76, p = 1.92 × 10−6), unaffected by
adjustment for BMI (OR = 6.66, p = 2.36 × 10−6) (C) rs7199182 is only
present in the eMERGE population and has a low LD with rs8050136
(r2 = 0.04) and is associated with chronic periodontitis before and after BMI
adjustment (no adjustment: p = 5.40 × 10−5; BMI adjustment:
p = 5.20 × 10−5).
Table 4 | Meta-analysis PheWAS results of rs8050136 for previously reported phenotypes associated with genetic variants.
Phenotype Cases Not adjusted for BMI Adjusted for BMI
p† OR (95% CI) p† OR (95% CI)
Attention deficit hyperactivity disorder 76 0.085 0.74 (0.52–1.04) 0.11 0.75 (0.53–1.06)
Pancreatic cancer 183 0.23 1.14 (0.92–1.40) 0.19 1.15 (0.93–1.42)
Alcoholism 267 0.37 1.08 (0.91–1.29) 0.32 1.09 (0.92–1.30)
Senile dementia 192 0.90 0.99 (0.80–1.22) 0.90 0.99 (0.80–1.22)
Osteoarthritis 6328 0.20 1.03 (0.98–1.08) 0.88 1.00 (0.95–1.06)
This table includes select phenotypes that have been previously reported in the literature. The Bonferroni alpha = 0.05 equates to a p-value of 4.95 × 10−5, and an
FDR of q = 0.05 gives a p-value of 2.48 × 10−4. OR, Odds ratio; CI, confidence interval.
†Values are not corrected for multiple testing.
in high correlation with rs8050136 (r2 > 0.8) have very simi-
lar results to rs8050136, which is what we would expect. There
are also SNPs that were associated with fibrocystic breast dis-
ease prior to adjustment for BMI. rs7199182, is in low LD
with rs8050136 (r2 < 0.01), showed significant associations with
chronic periodontitis before and after adjustment for BMI.
Further analysis of this SNP and its association with chronic peri-
odontitis will need to be investigated to validate this finding.
One important consideration of this analysis is the small over-
lap of genotyped SNPs between the BioVU and eMERGE pop-
ulation. There are multiple SNPs that are present in both
datasets and are highly correlated with rs8050136, but only
rs6499640, which is in weak LD with rs8050136 (r2 = 0.06),
was genotyped in both datasets. We are unable to impute the
BioVU. The lack of overlapping SNPs limits our sample size
to evaluate more of the potentially novel findings. Limitations
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caution interpretation of this study. Some of the case sizes were
small and will require larger populations to validate. PheWAS
analyses require robust EHR systems that can query patient
cohorts efficiently. We used ICD-9 codes for the determina-
tion of phenotypes, codes which can be unreliable, inaccurate,
and incomplete (Kern et al., 2006; Campbell et al., 2011); how-
ever, this could tend to result in missed, rather than false,
associations. In addition to the caveats of ICD-9 codes, there
are limitations of multiple hypothesis testing that come with
comparisons of over 1000 phenotypes. Significance corrections
like Bonferroni may be too strict; some of the near-significant
pleiotropic associations may, in fact, represent genuine associa-
tions. Further testing with larger populations and more carefully
defined phenotypes are needed to determine whether these asso-
ciations are real.
Here we demonstrate the use of the PheWAS method to illus-
trate pleiotropic effects of variation in the gene FTO. When
examining this gene with known pleiotropy, we were able to
reproduce previously-discovered associations and identify poten-
tial new associations, some of which appear independent of
obesity.
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